Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
PRESCRIBED FOR: Enoxaparin is used for preventing deep vein thrombosis
after abdominal, hip replacement, or
knee replacement surgeries, and in patients
with reduced mobility due to illness. It is used both in and out of the hospital
for treating deep vein thrombosis and pulmonary embolism. Enoxaparin also is
used for preventing a second heart attack and related complications after a
heart attack and for preventing blood clots in arterial stents.
SIDE EFFECTS:Common side effect associated with enoxaparin are:
PREPARATIONS: Enoxaparin is available in pre-filled syringes
containing 30, 40, 60, 80, 100, 120, and 150 mg. Multiple dose vial: 300 mg
STORAGE: All enoxaparin products should be stored at room temperature, between
15 and 30 C (59-86 F).
DOSING: Enoxaparin is administered by injection under the skin
(subcutaneous) or intravenously.
Preventing deep vein thrombosis after abdominal surgery: 40 mg
subcutaneous injection once daily.
Preventing deep vein thrombosis after knee replacement: 30 mg
subcutaneous injection every 12 hours.
Preventing deep vein thrombosis after hip replacement: 30 mg every 12
hours or 40 mg once daily by subcutaneous injection.
Preventing deep vein thrombosis in ill patients with limited mobility:
40 mg subcutaneous injection once daily.
Treatment of deep vein thrombosis or pulmonary embolism: 1 mg/kg every
12 hours or 1.5 mg/kg once daily by subcutaneous injection.
Outpatient treatment of deep vein thrombosis: 1 mg/kg subcutaneous
injection every 12 hours.
Treatment of severe heart attacks (ST elevation myocardial infarction or
STEMI): For patients under the age of 75, 30 mg intravenously plus 1 mg/kg
subcutaneously followed by 1 mg/kg every 12 hours (maximum of 100 mg for
each of the first two subcutaneous doses only). For patients over age 75,
0.75 mg/kg subcutaneously every 12 hours (maximum of 75 mg for each of the
first two subcutaneous doses only). All patients should receive aspirin.
Doses should be reduced in patients with impaired kidney function.
For coronary artery stent procedures (percutaneous coronary intervention
or PCI): Patients should receive 0.3 mg/kg during stent placement if the
last dose of enoxaparin was administered more than 8 hours before the